+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Epigenomics Market Report and Forecast 2023-2031

  • PDF Icon


  • 147 Pages
  • May 2023
  • Region: Global
  • Expert Market Research
  • ID: 5797856
The global epigenomics market value is anticipated to grow at a CAGR of 13.1% during the forecast period of 2023-2031.

Epigenomics Introduction

Epigenomics refers to the study of changes in gene expression caused by modifications to the DNA molecule itself, rather than changes in the DNA sequence. These modifications can be passed down through generations, and can also be influenced by environmental factors such as diet, toxins, and stress. Epigenomics is a rapidly growing field with the potential to revolutionize the diagnosis and treatment of many diseases.

The use of epigenomics in healthcare is still relatively new, but it has the potential to improve our understanding of disease mechanisms and lead to the development of more personalized and effective treatments. Epigenomic research is already being used to develop new cancer therapies and to identify biomarkers for disease diagnosis and prognosis.

As the field continues to grow, there is a growing interest in developing epigenetic therapies for a range of diseases, including cancer, autoimmune disorders, and neurological conditions. There is also a need for further development of epigenetic technologies and techniques to make them more accessible and cost-effective.

Overall, the field of epigenomics holds great promise for improving our understanding and treatment of many diseases, and is likely to continue to be an area of significant research and development in the coming years.

Epigenomics Market Scenario

Epigenomics is a field of science that studies the interactions between genes and the environment that can result in the activation or deactivation of genes, thereby influencing health and disease outcomes. Epigenomics involves the study of modifications to DNA and histone proteins that regulate gene expression, without altering the underlying genetic code. The use of epigenomic information is becoming increasingly important in understanding the development of diseases such as cancer, Alzheimer's disease, and diabetes, among others.

The global epigenomics market is expected to experience significant growth in the coming years, driven by factors such as increasing government funding for epigenomics research, rising prevalence of cancer and other chronic diseases, and growing demand for personalized medicine. The market is also expected to benefit from advancements in epigenomic technologies, including next-generation sequencing, mass spectrometry, and bioinformatics tools.

North America is expected to hold the largest share of the global epigenomics market, followed by Europe and the Asia-Pacific region. Factors driving the growth of the epigenomics market in North America include the presence of major market players, increasing government funding for epigenomics research, and rising prevalence of chronic diseases such as cancer and diabetes. The Asia-Pacific region is expected to experience significant growth in the coming years, driven by increasing government initiatives to support research and development activities, growing healthcare infrastructure, and rising healthcare spending in the region.

Epigenomics Market Segmentations

Market Breakup by Technology

  • Histone Methylation
  • Large Non-Coding RNA
  • MicroRNA Modification
  • DNA Methylation
  • Chromatin Structures
  • Others

Market Breakup by Product Type

  • Kits
  • Reagents
  • Enzymes
  • Others

Market Breakup by Application

  • Diagnostics
  • Pharmaceuticals

Market Breakup by End User

  • Hospitals and Clinics
  • Pharmaceuticals and Biotechnology Company

Market Breakup by Region

North America

  • United States of America
  • Canada


  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Key Trends in the Epigenomics Market

Some key trends in the Epigenomics market are:
  • Rising demand for personalized medicine: The growing awareness about personalized medicine is driving the growth of the Epigenomics market. Epigenomics offers a wide range of applications in the field of personalized medicine such as early detection, diagnosis, prognosis, and treatment of diseases
  • Increasing prevalence of cancer and other chronic diseases: The increasing prevalence of cancer and other chronic diseases is driving the demand for Epigenomics technologies. Epigenetic modifications play a crucial role in the development and progression of cancer and other chronic diseases, making it a promising tool for diagnosis, prognosis, and treatment of these diseases
  • Technological advancements: The development of advanced technologies in Epigenomics such as next-generation sequencing, DNA methylation analysis, histone modification analysis, and ChIP sequencing is driving the growth of the market. These advanced technologies offer high accuracy, sensitivity, and specificity, making them an ideal tool for Epigenomics research
  • Government initiatives and funding: The governments of various countries are investing heavily in Epigenomics research and development, which is driving the growth of the market. For instance, the National Institutes of Health (NIH) has launched various programs and initiatives to promote Epigenomics research and development
Growing collaborations and partnerships: The increasing collaborations and partnerships among key players in the market are driving the growth of the Epigenomics market. The collaborations and partnerships are aimed at developing new products and technologies, expanding the product portfolio, and increasing the market share of the companies.

Epigenomics Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • Epigenomics AG
  • Illumina, Inc
  • Merck KGaA
  • Zymo Research Corporation
  • Agilent Technologies, Inc.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Epigenomics Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Success Rate
5 Epigenomics Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Epigenomics Epidemiology (2016-2031)
5.3 Europe Epigenomics Epidemiology (2016-2031)
5.4 Asia-Pacific Epigenomics Epidemiology (2016-2031)
5.5 Latin America Epigenomics Epidemiology (2016-2031)
5.6 Middle East & Africa Epigenomics Epidemiology (2016-2031)
6 Global Epigenomics Market Overview
6.1 Global Epigenomics Market Historical Value (2016-2022)
6.2 Global Epigenomics Market Forecast Value (2023-2031)
7 Global Epigenomics Market Landscape
7.1 Epigenomics: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Epigenomics: Product Landscape
7.2.1 Analysis by Technology
7.2.2 Analysis by Product Type
7.2.3 Analysis by Application
7.2.4 Analysis by End User
8 Epigenomics Challenges and Unmet Needs
8.1 Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Epigenomics Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Epigenomics Market Segmentation
11.1 Global Epigenomics Market by Technology
11.1.1 Market Overview
11.1.2 Histone Methylation
11.1.3 Large Non-Coding RNA
11.1.4 MicroRNA Modification
11.1.5 DNA Methylation
11.1.6 Chromatin Structures
11.1.7 Others
11.2 Global Epigenomics Market by Product Type
11.2.1 Market Overview
11.2.2 Kits
11.2.3 Reagents
11.2.4 Enzymes
11.2.5 Others
11.3 Global Epigenomics Market by Application
11.3.1 Market Overview
11.3.2 Diagnostics
11.3.3 Pharmaceuticals
11.4 Global Epigenomics Market by End User
11.4.1 Market Overview
11.4.2 Hospitals and Clinics
11.4.3 Pharmaceuticals and Biotechnology Companies
11.4.4 Academic and Research Institutes
11.4.5 Others
11.5 Global Epigenomics Market by Region
11.5.1 Market Overview
11.5.2 North America
11.5.3 Europe
11.5.4 Asia Pacific
11.5.5 Latin America
11.5.6 Middle East and Africa
12 North America Epigenomics Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Epigenomics Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Epigenomics Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Epigenomics Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Epigenomics Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Epigenomics AG
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Illumina, Inc.
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Merck KGaA
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Zymo Research Corporation
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Agilent Technologies, Inc.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
24 Epigenomics - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket

Companies Mentioned

  • Epigenomics AG
  • Illumina, Inc.
  • Merck Kgaa
  • Zymo Research Corporation
  • Agilent Technologies, Inc.